SLDB, US83422E2046

Solid Biosciences stock fell 1.98 percent after Q2 EPS beat consensus

Published on 10/07/2026 at 05:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Solid Biosciences stock was last at USD 6.92 on October 6, 2026, with a USD 681.3 million market value. Q2 EPS beat consensus by USD 0.08.

SLDB, US83422E2046, Illustration mit AI erstellt.

Solid Biosciences stock (ISIN US83422E2046) fell 1.98 percent to USD 6.92 on Nasdaq on October 6, 2026, leaving the clinical-stage biotechnology company valued at USD 681.3 million. The move frames a company story built on pipeline progress, quarterly cash use and expectations for its gene therapy programs.

Q2 loss beats consensus

According to MarketBeat on September 8, 2026, Solid reported diluted EPS of negative USD 0.38 for the second quarter of 2026, compared with a consensus loss of USD 0.46. The USD 0.08 beat is the clearest quantified operating comparison in the latest reported period.

Finance figures for Q2 2026 show a net loss of USD 54.8 million and operating cash flow of negative USD 52.6 million. Cash and cash equivalents stood at USD 160.0 million on June 30, 2026, making liquidity the key counterweight to continued clinical spending.

Pipeline remains the valuation driver

Solid Biosciences develops precision genetic medicines for rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy, according to its Solid Biosciences investor-relations page. The business therefore carries a clinical-development profile rather than a revenue-growth profile, and quarterly EPS and cash balances remain more informative than sales growth.

The company disclosed an October 1, 2026 grant of 8,150 restricted stock units to one newly hired employee. The awards vest in four equal annual installments under the 2024 Inducement Stock Incentive Plan, according to Solid Biosciences.

Consensus target stays well above price

MarketBeat reported a Moderate Buy consensus on September 8, 2026, based on 11 Buy ratings and one Sell rating, with an average target of USD 18.18. That target lies 162.7 percent above the October 6 price of USD 6.92, a wide gap that reflects both the pipeline opportunity and the risks of clinical-stage development.

SLDB stock stays below its yearly high

SLDB was last at USD 6.92 on Nasdaq at 4:00 p.m. ET on October 6, 2026, down USD 0.14 from the prior close. The 52-week range was USD 3.79 to USD 11.45, while volume reached 1,188,683 shares.